[Updated on Apr. 18] Integration of CiNii Articles into CiNii Research

METGastric: a phase III study of onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative (HER2-) and MET-positive (MET+) adenocarcinoma of the stomach or gastroesophageal junction (GEC)

Journal

Related Articles

See more

Details

  • CRID
    1370286996377340929
  • Data Source
    • Crossref
Back to top